Side by side
Orforglipron vs SLU-PP-332
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Orforglipron | SLU-PP-332 | |
|---|---|---|
| What it is | The first GLP-1 pill that is a true small molecule. Approved in April 2026, and taken any time of day with no food or water restrictions. | A mouse compound that got a press release. It reproduced some effects of endurance training in mice, and no human has ever taken it. |
| EvidenceHow much human evidence exists, not how well it works. | Approved | Preclinical |
| Regulatory statusReviewed 2026-08-18 | Approved by the FDA on 1 April 2026 as Foundayo, for chronic weight management in adults with obesity, or overweight with a weight-related condition. The first non-peptide, small-molecule GLP-1 receptor agonist approved for weight loss. | Not approved anywhere and not in human trials. An academic research compound sold as a research chemical, typically as a powder with no pharmaceutical manufacturing behind it. |
| Routes | Oral | Oral, Subcutaneous |
| Half-life | 30 hours | Not recorded |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | $40.00/mg | $1.00/mg |
| Median per mg | $40.00/mg | $13.41/mg |
| Vendors with a price | 1 | 12 |
| Storage once mixed | Not applicable. This is a tablet. | A small molecule, not a peptide. Solvent choice varies, and vendors rarely say what theirs is. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.